

Exacerbations in cystic fibrosis: 4 · Non-cystic fibrosis bronchiectasis

A B Chang,¹ D Bilton²

¹ Department of Respiratory Medicine, Royal Children's Hospital and Child Health Division, Menzies School of Health Research, Charles Darwin University, Brisbane, Australia; ² Lung Defence Unit, Papworth Hospital NHS Trust, Cambridge, UK

Correspondence to: Dr A B Chang, Department of Respiratory Medicine, Royal Children's Hospital, Herston Road, Brisbane, Queensland 4029, Australia; annechang@ausdoctors.net

Received 4 May 2006
Accepted 27 November 2006

ABSTRACT

Bronchiectasis unrelated to cystic fibrosis (CF) is increasingly recognised as an important and major primary respiratory disease in developing countries. In affluent countries, bronchiectasis is also increasingly recognised in subsections of communities (such as indigenous peoples) as well as a co-existent disease/co-morbidity and disease modifier in respiratory diseases such as chronic obstructive pulmonary disease. The epidemiology, pathogenesis, prevention and management of exacerbations of non-CF bronchiectasis are reviewed. There are few data on all aspects of exacerbations in bronchiectasis. Some of the management issues are common to non-CF and CF bronchiectasis, but it would be unwise to extrapolate from CF studies to non-CF bronchiectasis. In some situations this may be harmful.

Bronchiectasis, previously termed an “orphan disease”, is increasingly recognised as a major cause of respiratory morbidity, not only in developing countries^{1–2} but also in children and adults in affluent countries.^{3–7} Bronchiectasis unrelated to cystic fibrosis (CF) is caused by—or associated with—many aetiologies ranging from congenital/genetic illness (primary immunodeficiency, primary ciliary dyskinesia, Mounier-Kuhn syndrome) to retained airway foreign body. Also, the presence of bronchiectasis in common respiratory diseases such as chronic obstructive pulmonary disease (COPD)⁸ and uncommon respiratory diseases such as bronchiolitis obliterans⁹ or sarcoidosis¹⁰ as well as systemic disease (eg, autoimmune diseases such as rheumatoid arthritis¹¹) is increasingly recognised. Even with extensive investigation, a significant number of patients retain the label “idiopathic bronchiectasis”.^{12–13}

Those with bronchiectasis suffer from recurrent acute exacerbations, some requiring treatment in hospital.¹⁴ Unless otherwise stated, all data presented are specific to non-CF bronchiectasis. Clinically, major pulmonary symptoms and signs of acute exacerbations in bronchiectasis are similar to that of CF—increased cough and/or wheeze, sputum production, dyspnoea and lethargy. In people with severe exacerbations, especially in the presence of severe bronchiectasis, hypoxaemia may also be present. However, the definition of an acute exacerbation is not standardised, and it has been variably defined to include some or all of the following: increased cough, sputum production/volume or purulence, dyspnoea, haemoptysis, or deterioration in spirometry, chest signs, radiographic changes.^{15–16} Other possible modalities for assessing acute exacerbation are discussed in table 1.

EPIDEMIOLOGY OF EXACERBATIONS

Hospital admissions across time and countries

Hospital admissions for bronchiectasis have decreased with time for both children and adults in affluent countries.⁷ In a Finnish study, new occurrence, admissions and number of days in hospital for bronchiectasis have decreased.⁷ There were 143 and 87 admissions per million inhabitants in 1972 and 1992, respectively. In the period between 1983 and 1992, hospitalisation occurrence was 4.9/million person-years at age 0–14 years, 103.8 at ≥65 years and 38.9 in the total population.¹⁷ Current prevalence data on hospital admissions specifically for bronchiectasis are unavailable, but there is a general impression among respiratory physicians that the prevalence in the young (and, hence, presumably exacerbations and hospital admissions) is increasing.^{18–20} A case-control study in adults matched for age, gender and co-morbidity found that those with bronchiectasis were hospitalised for an additional 2 days/year (95% confidence interval (CI) 1.7 to 2.3),¹⁹ and the difference between the groups in the cost of inpatient care was US\$3200/year. In developing countries, hospitalisation for exacerbation of bronchiectasis is still common.⁸

Bronchiectasis as a co-existing illness or co-morbidity

Bronchiectasis is a common complication of a variety of diseases. When it is present with an underlying disorder, increased morbidity and mortality have been described.^{8–10,21} In diseases like COPD, the presence of bronchiectasis is common^{8,22} in population cohorts and its presence increases the severity⁸ and frequency²³ of pulmonary exacerbations. In a primary care study, O'Brien and colleagues described the radiological presence of bronchiectasis in 29% of 110 adults who had mild to severe COPD.²² In a hospital-based study (n = 54), 50% of adults with moderate to severe COPD had bronchiectasis, and those with bronchiectasis were more likely to have severe exacerbations, airway chronic infection and increased sputum inflammatory markers.⁸ This raises two issues: (1) it is possible that some people may have bronchiectasis as a primary aetiology of airway obstruction rather than COPD; and (2) during an exacerbation, distinguishing an exacerbation of bronchiectasis from a COPD exacerbation can be artificial, especially when the disease is severe.

Sputum and airway markers as risk factors for exacerbations

The relationship between respiratory infections and bronchiectasis was described decades ago.²⁴

Table 1 Modalities for monitoring bronchiectasis

Modality	Description	Limitation
Clinical		
Symptoms and signs	Increased cough, sputum production/volume or purulence, dyspnoea, lethargy, haemoptysis, chest pain ⁷⁰ or deterioration in chest signs	Perception issues ⁷⁴ and likely insensitive
Lung function		
Spirometry	Classically obstructive, easy to do and use when aged >6 years	Insensitive and patients can have structural airway changes on HRCT despite normal spirometry ⁷⁵
QOL	SGRQ validated for bronchiectasis ⁷¹ and used in studies ^{29 69 76}	No bronchiectasis-specific QOL exists
Radiology		
Chest radiograph	Increased markings, lesions, scarring, atelectasis ⁷⁷	Poor sensitivity ⁷⁸
HRCT scan	Many scoring systems for bronchiectasis exist, ^{79 80 81} "best" unknown. Exacerbation frequency related to bronchial wall thickening ⁸¹ children ⁸³	Impractical for regular use; issues with radiation dose, ⁸² especially in children ⁸³
Airway inflammation/oxidation		
Exhaled H ₂ O ₂	Elevated in bronchiectasis, negative correlation with FEV ₁ ⁸⁴	More studies required Steroids have no effect on H ₂ O ₂
Exhaled CO	Elevated in bronchiectasis ⁸⁵	More studies required
Exhaled NO	Decreased, normal and increased values described. Correlation with disease severity if not on steroids ⁸⁶	Inconsistent data. Sensitivity unknown, currently unsuitable as a monitoring tool for bronchiectasis.
Sputum indices	Airway neutrophilia reduces with antibiotic treatment, ⁸⁹ tumour necrosis factor α , interleukin-8, neutrophil elastase also decreases with antibiotics ⁸⁹	Useful when asthma or ABPA ⁸⁷ suspected as cause of exacerbation; eg, if eosinophilia present, systemic corticosteroids likely to be beneficial
AHR		
Methacholine	Increased AHR ⁴⁷	Direct tests for AHR increasingly recognised to be non specific ⁸⁸
Cardiac assessment	Left ventricular diastolic dysfunction. ⁸⁹ Correlates with disease severity	No prospective medium/long term cohort available to define role
Exercise test	Decreased exercise tolerance, ⁹⁰ lower aerobic capacity and maximal ventilation ⁹¹	No prospective medium/long-term cohort available to define role

ABPA, allergic bronchopulmonary aspergillosis; AHR, airway hyper-responsiveness; CO, carbon monoxide; FEV₁, forced expiratory volume in 1 s; H₂O₂, hydrogen peroxide; HRCT, high-resolution computed tomography; NO, nitric oxide; QOL, quality of life; SGRQ, St George's respiratory questionnaire

The "role of bacteria in the pathogenesis and progression of acute and chronic lung infection" has been well summarised by Stockley.²⁵ Data specific for bronchiectasis exacerbations (as opposed to infections contributing to the pathogenesis of development of bronchiectasis) are less known. Are there any bacteriological or sputum markers that influence exacerbation frequency and/or severity? Hill and colleagues found that adult patients whose purulent sputum became mucoid after treatment had a longer time to next exacerbation (median 6.5 months, range 1–11) than those whose sputum purulence did not clear.²⁶ The sputum pathogen isolation/chronic infection rate for paediatric studies varies from 53% to 67%,^{1 4} and that for adult cohorts from 88% to 100%.^{12 27 28} The presence of *Pseudomonas aeruginosa* is associated with more severe disease in some studies,^{27 29 30} but not in one paediatric study.¹³ *P aeruginosa* occurs less frequently in paediatric cohorts^{4 13} than

in adult cohorts^{27 28} (0–11% vs 4–33%). In the study by Wilson and colleagues,²⁹ adults colonised with *P aeruginosa* were no more likely to have infective exacerbations but were likely to have been hospitalised in the previous year compared with those colonised with *Haemophilus influenzae* or other bacterial pathogens. There are no similar paediatric data available, and we could not find any prospective study that has examined the effect of *P aeruginosa* or other pathogen eradication on exacerbation frequency. The presence of increased sputum interleukin (IL)-6 in the stable state is related to increased frequency of exacerbations in adults.⁸

Other risk factors for exacerbations of bronchiectasis

The frequency of exacerbations is higher in more severe disease³¹ and unmanaged bronchiectasis.¹ In a Turkish study of 111 children, "intensive medical treatment" (prompt antibiotic use, physiotherapy, bronchodilators) reduced exacerbation rates from a mean (SD) of 6.6 (4.0) to 2.9 (2.9) per year.¹ There are few other specific data on risks for exacerbations. Factors that can lead to bronchiectasis may theoretically also exacerbate bronchiectasis and include poor nutrition, poverty, environmental factors and some co-existent diseases.

There are no studies on the influence of nutrition on bronchiectasis exacerbations. However, it is known that poor nutrition (macronutrients and micronutrients) affects both innate and adaptive immune function³² and childhood morbidity and mortality.³³ Malnutrition of both macronutrients and some micronutrients increases infection risks as it creates an immune deficient state and leads to the malnutrition/infection/malnutrition cycle.³⁴ Also, evidence from studies on nutrition in other chronic respiratory diseases³⁵ supports the clinical observation that poor nutrition is a risk factor for pulmonary exacerbations in people with bronchiectasis.

It has been well documented that increased poverty,³⁶ pollution (environmental or occupational³⁷) tobacco smoke,³⁸ biomass combustion³⁹ and other public health issues are associated with increased respiratory infections and/or bronchiectasis. Environmental pollutants are well known to exacerbate any chronic respiratory insufficiency.⁴⁰ However, there are no specific studies of the role of the above on bronchiectasis exacerbations.

Bronchiectasis and other forms of suppurative lung disease have been described in individuals with neurological and neuromuscular conditions that reduce the effectiveness of cough. In such cases, the increased risk of aspirating oropharyngeal contents makes oral hygiene important. In a study of 10 children with such conditions, Brook noted that 6 had evidence of poor oral hygiene.⁴¹ Similar data have been reported in adults with COPD where periodontal disease was associated with more severe airway obstruction.⁴² There are no studies specifically on the effect of oral hygiene on pulmonary exacerbations of bronchiectasis.

People with bronchiectasis have an increased incidence of other co-morbidities such as gastro-oesophageal reflux (GOR)⁴³ and "asthma-like" disease.⁶ These would theoretically be a risk factor for exacerbations, but how much these contribute to frequency and/or severity of exacerbations has not been studied. "Asthma-like" disease, present in 21–39% of bronchiectasis cohorts,^{44 45} is an independent risk factor for accelerated pulmonary decline in adults²¹ and children.⁴⁶ Increased airway responsiveness is associated with more severe disease.⁴⁷ A study from the Middle East found that patients with bronchiectasis who had an obstructive pattern on spirometric testing were significantly more likely to have an exacerbation requiring

admission to hospital than those with non-obstructive airways (6 vs 2 hospital admissions, respectively).⁴⁸ These co-existent relationships, however, need to be interpreted with caution; for example, the treatment for GOR only modestly influenced cough⁴⁹ and asthma⁵⁰ outcomes in randomised controlled trials in contrast to cohort studies.

PATHOGENESIS OF EXACERBATIONS

Triggers of bronchiectasis exacerbations have not been studied. It is commonly assumed that any of the risk factors presented above can trigger an exacerbation, and that a pathogen is always involved at some point of the exacerbation. In Cole's "vicious circle hypothesis" the pathogenesis of bronchiectasis includes an initial insult to the lower airways, impaired mucociliary clearance, microbial colonisation/infection, bronchial obstruction and a normal or exaggerated inflammatory response.⁵¹ There is indirect support for Cole's model.

Persistent inflammation plays a role in deterioration of lung function²⁵ in bronchiectasis.⁵² The airways of adults with bronchiectasis have increased pro-inflammatory mediators; endobronchial biopsy specimens from adults with bronchiectasis who are clinically stable have increased neutrophil matrix metalloproteinases-8 and -9.⁵³ Their bronchoalveolar lavage fluid contains increased levels of neutrophils, elastase, myeloperoxidase, tumour necrosis factor (TNF) α , interleukin (IL)-8 and IL-6 compared with controls.⁵⁴ Serum levels of adhesion molecules E-selectin, intercellular adhesion molecule-1 and vascular adhesion molecule-1 are also raised, with the former two inversely related to forced expiratory volume in 1 s (FEV₁).⁵⁵ Those with more severe bronchiectasis (earlier diagnosis, lower FEV₁ and varicose-cystic bronchiectasis) are more likely to be colonised with pathogens⁵⁶ and have more intense inflammation than those not colonised.⁵⁴ Sputum purulence increases during exacerbations and decreases with treatment for exacerbation.²⁶ Those with less purulent sputum in the non-acute state have a longer period before the next exacerbation.²⁶ Several groups have shown an alteration in neutrophilic inflammatory profiles after antibiotic treatment.^{57–58} In the study reported by Ip and colleagues,⁵⁷ patients with acute exacerbations of bronchiectasis treated with oral antibiotics had increased sputum neutrophil chemotactic activity and elastolytic activity during an exacerbation. Watt and colleagues⁵⁹ also showed that concentrations of TNF α , IL-8 and neutrophil elastase in sputum supernatant were significantly reduced at day 14 of antibiotics compared with initiation of treatment. Lung permeability decreased in two of the six patients whose sputum was cleared of pathogens following treatment with antibiotics.⁶⁰

The above data therefore suggest that airway infection and inflammation are important during an exacerbation. However, it is unknown what proportion of bronchiectasis exacerbations are triggered by an infection and, if so, the type of infection. It is also unknown how often viral infections trigger an exacerbation. Klingman and colleagues⁶¹ prospectively performed bimonthly sputum cultures as well as during an exacerbation in 28 adults. They found that a subset of six patients was repeatedly colonised with *Moraxella catarrhalis* but there was no relationship between the viable numbers of bacteria recovered and the exacerbation or clinical status, although antibiotic therapy resulted in reduced viable bacterial numbers at the end of the treatment. During the total of 18 exacerbations, the pattern of *M. catarrhalis* cultured was inconsistent.

Based on their findings that adults treated with ciprofloxacin had a better clinical outcome than those treated with amoxicillin, Chan and colleagues⁶² suggested that *P. aeruginosa*

is an important pathogen during an infective exacerbation. Mycobacteria have been reported as a common cause of exacerbations⁶³ and as a cause of pulmonary deterioration.⁶⁴ The Hong Kong series reported the presence of non-tuberculous mycobacteria (NTM) in 13% of 91 adults⁶³ whereas the London series reported NTM in 2% of their prospective study of 100 patients.⁶⁴ Fungal infection and allergic bronchopulmonary aspergillosis, which can itself cause bronchiectasis, have also been implicated in case studies.⁶⁵ In the absence of adequate double-blind placebo-controlled randomised trials and good prospective data, the role of these particular organisms in acute exacerbations remains unclear.

Patients may remain colonised with the same microbiological species both in the stable state and during acute exacerbations. The possible triggers for the exacerbation in that setting include viral infection or infection with a new bacteria or a change in bacterial strain with associated variability in bacterial epitopes important for immune recognition. Alternatively, there may simply be rapid multiplication of the existing colonising species or "planktonic bloom" in the case of *P. aeruginosa* in CF.⁶⁶

PREVENTION OF ACUTE EXACERBATIONS

In people with diseases which predispose to the development of bronchiectasis (such as primary ciliary dyskinesia and primary immunodeficiency), prevention of the development of bronchiectasis through modalities that prevent or limit respiratory infections is a long-term management goal.^{67–68} Ellerman and Bisgaard⁶⁷ showed, in their cohort of people with primary ciliary dyskinesia, that adults who were diagnosed later had significantly poorer lung function. They concluded that progressive deterioration in lung function occurs with inadequate treatment of symptoms and that lung function can be maintained with appropriate antibiotic treatment and regular physiotherapy. This further supports Cole's vicious cycle hypothesis⁵¹ that further or ongoing infection and resultant inflammation can lead to further lung destruction. Thus, prevention of recurrent exacerbations is important for maintenance of lung function. Also, exacerbations have a negative impact on quality of life issues and healthcare costs.^{14–17–19} Strongest predictors of quality of life in clinically stable bronchiectasis include dyspnoea, FEV₁ and sputum production.⁶⁹ In an exacerbation where all three factors are generally worse,⁷⁰ quality of life would decrease. Furthermore, Wilson *et al* demonstrated a clear relationship between lower quality of life in the St George's questionnaire and increasing numbers of exacerbations.⁷¹

In many diseases the prevention of acute exacerbations is linked to early recognition and close monitoring of disease activity/severity.^{72–73} These are less defined in bronchiectasis than in diseases such as asthma. Current available modalities and their limitations are presented in table 1. Most of the studies were performed during the stable phase and most—but not all—studies showed increased dysfunction with decreasing pulmonary function. Thus, while some may be considered as markers of disease severity and possibly reflective of exacerbations, more research is required and the clinical utility of these tests remains undefined.

Modalities for prevention of exacerbations

General

It is generally accepted that earlier diagnosis, close monitoring and intensive therapy reduces the frequency and/or severity of exacerbations and slows pulmonary decline.^{1–67} However, there is limited published evidence. In 101 children with bronchiectasis Li *et al*¹³ found that determination of the underlying aetiology of

Table 2 Treatments for prevention of exacerbations

	Evidence type/study	Summary of results	Notes
Antimicrobial agents			
General	Cochrane review, ⁹⁹ other systematic review ⁹³	Generally beneficial (see text)	Resistance and nebulised tobramycin poorly tolerated in some ⁹⁵
Macrolides ¹⁶	Randomised non-placebo trial (n = 12) azithromycin for 6 months vs usual treatment	Exacerbations significantly reduced in treatment arm compared with non-treatment arm (16 vs 5)	
Nebulised tobramycin ⁹⁴	Double blind crossover RCT in 30 patients with <i>P aeruginosa</i> , 6 months each	Number and days of admissions less in tobramycin arm but no difference in number of exacerbations	Resistance and nebulised tobramycin poorly tolerated in some ⁹⁵
Anti-inflammatory agents			
Indomethacin ¹⁰⁰	Cohort study, 25 mg three times daily for 28 days	Reduction in peripheral neutrophil chemotaxis; no change in sputum albumin, elastase, myeloperoxidase or exacerbation	
Mucolytics			
Bromhexine	Cochrane review ¹⁰¹	Studies only in acute phase	Not universally available
rhDNAse	Systematic review ^{101 102}	Increased exacerbation rate	
Airway clearance			
Chest physiotherapy	Cochrane review ¹⁰³	Two small trials on bronchiectasis, exacerbation rate not reported	
Inhaled hyperosmolar agents	Cochrane review, ¹⁰⁴ additional RCT (non-blinded) using 7% HS ¹⁰⁵	Neither study reported on exacerbation rates	
Asthma therapies			
Inhaled corticosteroids (ICS)	Cochrane review ¹⁰⁴ and double blind RCT using 500 µg fluticasone twice daily ¹⁵	Reduced exacerbation rate only seen in those with <i>P aeruginosa</i> infection. ¹⁵ No significant effect of ICS in Cochrane review ¹⁰⁴	Limited applicability in children-high dose ICS and children less likely to have <i>P aeruginosa</i>
Oral corticosteroids	Cochrane review ¹⁰⁶	No RCTs	No data*
Anticholinergics	Cochrane review ¹⁰⁷	No RCTs	No data*
β ₂ -agonists	Cochrane review ^{108 109}	No RCTs	No data*
LTRA	Cochrane review ¹¹⁰	No RCTs	No data*
Physical training	Cochrane review ¹¹¹ and RCT ¹¹² which was included in Cochrane as an abstract (data changed)	No data on exacerbation	Pulmonary rehabilitation improves exercise tolerance, no additional advantage of simultaneous inspiratory muscle training
Environmental modification	No data*		Assumed beneficial (see text)
Oxygen (domiciliary)	No data as sole therapy*	Consider data from COPD showing benefit in survival but no effect on exacerbation ^{113 114}	
Surgery	Cochrane review ¹¹⁵	No RCTs. Cohort studies suggest beneficial in selected cases. ¹ Annual exacerbation rate reduced from 5.9 to 2.3	Reduction in exacerbation rate similar in medically treated group. ¹¹⁶ Adverse events of surgery ^{115 117 118}
Vaccines	No data*	Advocated as vaccines prevent respiratory infections ¹¹⁹	
Ventilatory assistance			
NPPV†	Retrospective case controlled study on NPPV with oxygen ¹²⁰	Reduced hospitalisation rate, no difference in mortality	No effect on survival
	Retrospective study using NPPV with oxygen ¹²¹	Reduced hospitalisation days, improved QOL	PacO ₂ stabilised after NIV but no change on Pao ₂
Model of care			
Nurse-led	Cochrane review ¹²²	No difference in infective exacerbations but increase in hospitalisations in nurse-led care compared with doctor-led care	Increased healthcare cost implications
Sputum surveillance	No data*	Suggestions that this should be done ¹²³ (frequency undefined)	Chronic infection or colonisation prevalent (see text)
Psychosocial	No data*		34% have depression, anxiety or both ⁷⁴

COPD, chronic obstructive pulmonary disease; HS, hypertonic saline; LTRA, leucotriene receptor antagonist; NPPV, non-invasive positive pressure ventilation; QOL, quality of life; RCT, randomised controlled trial.

*No other data specific to exacerbation based on single reviewer search on PubMed (March 2006).

†A review article suggested that non-invasive positive pressure ventilation is probably beneficial in reducing exacerbation days/episodes in those with chronic respiratory failure, although the data are scarce.¹¹³

bronchiectasis can lead to distinct and individualised change in management; subsequent exacerbation frequency or severity was not determined in the study but, based on other data, appropriate therapy improves prognosis⁶⁷ which is associated with reduced exacerbations.¹ Exacerbation frequency per year is directly related to bronchial wall thickening on high-resolution computed tomographic (HRCT) chest scans,³¹ and severe bronchial wall

thickness was the most adverse prognostic determinant in a study using serial chest HRCT scans.⁹²

Antimicrobial agents

The systematic review by Yang and colleagues⁹³ (search date March 2003) described six studies on antibiotics used in the

Table 3 Treatments for acute exacerbations of bronchiectasis

	Evidence or study	Summary data	Limitations
Antimicrobial agents	Systematic review ⁹³	Beneficial (see text)	
Anti-inflammatories	*No data		
Mucolytics			
Bromhexine	Cochrane review ¹⁰¹	High doses of bromhexine with antibiotics eased difficulty in expectoration, reduction in sputum production	Not universally available
rhDNase	Systematic review ^{101 102}	No studies in acute phase. ^{101 102} Note increased exacerbation rate when used in non-acute phase	Adverse effects more common in the group receiving rhDNase
Airway clearance			
Chest physiotherapy	Cochrane review ¹⁰³	No data*	
Inhaled hyperosmolar agents	Cochrane review ^{104 105}	One RCT using single mannitol dose in stable bronchiectasis, ¹²⁷ improved airway clearance; one study on 7% HS as adjunct to physiotherapy. ¹⁰⁵ Sputum weights, ease for expectoration, viscosity better in HS group	
Asthma therapies			
Inhaled corticosteroids	No data during pulmonary exacerbation*	See table 2 for other data	
Oral corticosteroids	Cochrane review ¹⁰⁶	No RCTs	No other data*
Anticholinergics	Cochrane review ¹⁰⁷	No RCTs	No other data*
β_2 agonist	Cochrane review ^{108 109}	No RCTs	No other data*
LTRA	Cochrane review ¹¹⁰	No RCTs	No other data*
Methylxanthines	Cochrane review ¹²⁸	No RCTs	No other data*
Exercise/physical training	No data*		
Oxygen	No data*	Consider data from COPD	
Surgery	No data*		
Ventilatory assistance			
BTS guidelines ¹²⁶	See text		

HS, hypertonic saline; LTRA, leucotriene receptor antagonist; RCT, randomised controlled trial; rhDNase, recombinant human deoxyribonuclease.

*No other data specific to acute exacerbation management based on single reviewer search (up to March 2006).

stable phase; only five of these trials used antibiotics for ≥ 4 weeks and, of these, two used antibiotics for ≥ 6 months. The MRC 1957 study compared the prolonged use of either oxytetracycline or penicillin with placebo over 12 months. Oxytetracycline was more effective than penicillin or placebo in reducing 24 h sputum volume, cough, dyspnoea and days confined to bed.⁹³ A trial of 38 patients randomised to either amoxicillin or placebo for 32 weeks showed improvement in the amoxicillin group with a reduction in the severity of exacerbations.⁹³ We found three further studies^{16 94 95} subsequent to the search date above. Two of the three studies^{16 94} examined for exacerbations (table 2). Exacerbation frequency was reduced in the azithromycin study¹⁶ but not in the inhaled tobramycin study.⁹⁴ A non-placebo 12-month trial in non-CF adult patients with chronic *Pseudomonas* infection showed a reduced number of hospitalisations and days of admission (mean (SE) 0.6 (1.5) vs 13.1 (34.8) days) in those on continuous treatment with either inhaled ceftazidime or tobramycin compared with those receiving symptomatic treatment (ie, treatment only when symptomatic (2.5 (2.1) and 57.9 (41.8)).⁹⁶ The sole randomised controlled trial of >4 weeks in childhood bronchiectasis did not examine the exacerbation rate.⁹⁷ In a study by Koh and colleagues,⁹⁷ 25 children were randomised to receive 12 weeks of roxithromycin (4 mg/kg twice a day) or placebo. A significant improvement in sputum purulence and leucocyte scores and airway hyper-responsiveness but not FEV₁ occurred in the roxithromycin group. A Cochrane review on the use of prolonged antibiotics for purulent bronchiectasis in both children and adults also found that, although the use of prolonged antibiotics conferred a small benefit, particularly in terms of sputum characteristics, exacerbation rates were similar between the antibiotic and placebo arms.⁹⁸ Thus, current data suggest that maintenance antibiotics are likely to be beneficial

in preventing the frequency and/or the severity of exacerbations, at least in some patients. However, long-term intervention trials have not been conducted in either adults or children with bronchiectasis and further studies are required before this can be recommended for all patients.

There are even fewer data on modalities other than antibiotics for preventing exacerbations, as summarised in table 2. The table and this review do not include specific therapies for underlying aetiologies such as primary immune deficiency; in these circumstances specific therapies such as regular immunoglobulin infusions in hypogammaglobulinaemia reduce pulmonary exacerbations.⁶⁸

TREATMENT OF ACUTE EXACERBATIONS

There is a glaring lack of studies on the treatment of acute exacerbations, and those available are often insufficiently powered. Thus the “lack of evidence” as opposed to “evidence for lack of effect” is highly relevant for this subject. Management of bronchiectasis has largely been extrapolated from data on CF. While extrapolation appears reasonable for some treatments such as use of antibiotics and chest physiotherapy, it would seem less reasonable for other treatments as the rheology, sputum and electrolyte contents of CF sputum differ from that of non-CF sputum. Indeed, harm has been shown in adults randomised to receive rhDNase compared with placebo,¹⁰¹ which is in contrast to the beneficial effect of rhDNase for CF.¹²⁴ In a double-blind, randomised, placebo-controlled, multicentre study for 24 weeks in 349 adults with bronchiectasis, those given rhDNase had a higher exacerbation rate and hospitalisation rate (relative risk 1.35 and 1.85, respectively) and more rapid pulmonary decline (decrease in FEV₁ 3.6% in rhDNase group, 1.6% in placebo group).¹²⁵

Irrespective of the evidence, the current standard therapy for acute exacerbations is primarily targeted at prolonged antimicrobials and airway clearance techniques. Studies on bacterial chronic infection suggest that empirical antibiotic coverage for exacerbations in adults should include *H influenzae* and *P aeruginosa*.²⁸ The systematic review by Yang and colleagues (search date March 2003) for adults stated: "... in clinical practice, exacerbations respond well to broad-spectrum antibiotics effective against *P aeruginosa*, *H influenzae* and *S aureus* in conventional doses".⁹³ They also examined the question: "which antibiotics work in acute exacerbations of bronchiectasis?" and concluded that there are "no published RCTs comparing antibiotics with placebo in acute exacerbations of bronchiectasis".⁹³ Only four studies were performed in an acute exacerbation and all studies compared quinolones with β -lactam drugs for 7–10 days.⁹³ Quinolones were generally superior, but their long-term use should be considered cautiously because of the risk of antibiotic resistance. Since the review, a further search (March 2006, done by single reviewer) found no further studies relevant to treatment for acute exacerbations.

Management of acute exacerbations includes a search for any treatable trigger factor (discussed above). A summary of the data on the various options for treating acute exacerbations are presented in table 3. In severe and selective situations, oxygen therapy and, rarely, ventilatory assistance are also used. The British Thoracic Society (BTS) guidelines state: "A trial of non-invasive ventilation may be undertaken in patients with a respiratory acidosis (pH <7.35, H^+ >45 nmol/l) secondary to an acute exacerbation of bronchiectasis, but excessive secretions are likely to limit its effectiveness and it should not be used routinely in bronchiectasis".¹²⁶ The survival of patients with bronchiectasis after the first ICU stay for respiratory failure is poor; 19% died during their ICU stay and 1-year mortality was 40% (risk was particularly increased in older (>65 years) patients and those on long term oxygen).¹¹⁸

Clinical and research questions

Research into the prevention and treatment of exacerbations of bronchiectasis requires an international consensus on the definition of an exacerbation which is validated against sputum or breath inflammatory markers, as well as clinical and spirometric parameters. Once we have a well validated definition, the investigation of the triggers and causes of exacerbations can be studied. It will be particularly helpful in determining the effect of viruses in this setting, and in elucidating the variability of bacterial strains and their contribution to exacerbations in bronchiectasis.

The validation of end points for studies of exacerbation treatments is a further obstacle to the conduct of large randomised controlled trials. While clinicians recognise the parameters of sputum volume and colour as key clinical indicators of successful treatment in non-CF bronchiectasis, these have not been validated sufficiently to be acceptable end points to regulatory bodies. This is particularly important as FEV₁ is a less sensitive measure in acute exacerbations of bronchiectasis (in contrast to CF). The measurement of small airways function is worthy of further investigation and validation in this setting.

It is critical that, in all these areas, studies are performed in both children and adults in sufficient numbers to identify similarities and differences in treatment effects. Randomised controlled trials are required to assess the benefits of adjunctive therapies during acute exacerbations. We have no information currently, for example, on the risks and benefits of the addition

of oral steroids during an acute exacerbation. Finally, at the most simple level, our current antibiotic treatments for acute exacerbations still require rigorous assessment. We do not know the optimal duration of antibiotic therapy for acute exacerbations—not only in terms of optimum short-term benefit but, importantly, in terms of delaying the time to next exacerbation. Future trials of treatment in acute exacerbations must include sufficient follow-up to assess the time to next exacerbation, which is an emerging clinical trial end point in studies of patients with CF.¹²⁹

CONCLUSIONS

Acute pulmonary exacerbations are now recognised as an important outcome measure in bronchiectasis, just as they are in other respiratory diseases such as COPD,⁷³ CF and asthma. Exacerbations have a significant impact on quality of life, acutely reduce respiratory function, result in hospitalisations and are a likely contributor to long-term respiratory decline. However, contributors to these exacerbations are poorly understood and evidence-based care for the prevention and management of exacerbations is scarce. Future clinical and research challenges include the ability to better define and monitor exacerbations, understanding the causes of exacerbations, monitoring of disease and improved management of exacerbations.

Acknowledgements: The authors thank Associate Professor Scott Bell for his input, provision of several references and critique of the manuscript, and Dr Margaret McElrea for her critique of the manuscript.

Funding: ABC is funded by the Australian National Health Medical Research Council and the Royal Children's Hospital Foundation.

Competing interests: None.

REFERENCES

1. Karadag B, Karakoc F, Ersu R, *et al*. Non-cystic-fibrosis bronchiectasis in children: a persisting problem in developing countries. *Respiration* 2005;**72**:233–8.
2. Karakoc GB, Yilmaz M, Altintas DU, *et al*. Bronchiectasis: still a problem. *Pediatr Pulmonol* 2001;**32**:175–8.
3. Callahan CW, Redding GJ. Bronchiectasis in children: orphan disease or persistent problem? *Pediatr Pulmonol* 2002;**33**:492–6.
4. Edwards EA, Asher MI, Byrnes CA. Paediatric bronchiectasis in the twenty-first century: experience of a tertiary children's hospital in New Zealand. *J Paediatr Child Health* 2003;**39**:111–7.
5. Chang AB, Grimwood K, Mulholland EK, *et al*. Bronchiectasis in Indigenous children in remote Australian communities. *Med J Aust* 2002;**177**:200–4.
6. Singleton RJ, Morris A, Redding G, *et al*. Bronchiectasis in Alaska native children: causes and clinical courses. *Pediatr Pulmonol* 2000;**29**:182–7.
7. Saymajakangas O, Keistinen T, Tuuponen T, *et al*. Bronchiectasis in Finland: trends in hospital treatment. *Respir Med* 1997;**91**:395–8.
8. Patel IS, Vlahos I, Wilkinson TM, *et al*. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2004;**170**:400–7.
9. Chang AB, Masel JP, Masters B. Post-infectious bronchiolitis obliterans: clinical, radiological and pulmonary function sequelae. *Pediatr Radiol* 1998;**28**:23–9.
10. Lewis MM, Mortelliti MP, Yeager H Jr, *et al*. Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients. *Sarcoidosis Vasc Diffus Lung Dis* 2002;**19**:154–9.
11. Zrour SH, Touzi M, Bejjani I, *et al*. Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis. Prospective study in 75 patients. *Joint Bone Spine* 2005;**72**:41–7.
12. Pasteur MC, Helliwell SM, Houghton SJ, *et al*. An investigation into causative factors in patients with bronchiectasis. *Am J Respir Crit Care Med* 2000;**162**:1277–84.
13. Li AM, Sonnappa S, Lex C, *et al*. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? *Eur Respir J* 2005;**26**:8–14.
14. Saymajakangas O, Keistinen T, Tuuponen T, *et al*. The course of childhood bronchiectasis: a case report and considerations of hospital use. *Int J Circumpolar Health* 1998;**57**:276–9.
15. Tsang KW, Tan KC, Ho PL, *et al*. Inhaled fluticasone in bronchiectasis: a 12 month study. *Thorax* 2005;**60**:239–43.
16. Cymbala AA, Edmonds LC, Bauer MA, *et al*. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. *Treat Respir Med* 2005;**4**:117–22.

17. **Saynajakangas O**, Keistinen T, Tuuponen T, *et al*. Evaluation of the incidence and age distribution of bronchiectasis from the Finnish hospital discharge register. *Cent Eur J Public Health* 1998;**6**:235–7.
18. **Town GI**, Crane J. Respiratory health and lung research in New Zealand. *Chron Respir Dis* 2006;**3**:167–9.
19. **Weycker D**, Edelsberg J, Oster G, *et al*. Prevalence and economic burden of bronchiectasis. *Clin Pulm Med* 2005;**12**:205–9.
20. **King P**, Holdsworth S, Freezer N, *et al*. Bronchiectasis. *Intern Med J* 2006;**36**:729–37.
21. **Keistinen T**, Saynajakangas O, Tuuponen T, *et al*. Bronchiectasis: an orphan disease with a poorly-understood prognosis. *Eur Respir J* 1997;**10**:2784–7.
22. **O'Brien C**, Guest PJ, Hill SL, *et al*. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. *Thorax* 2000;**55**:635–42.
23. **Gursel G**. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease? *Heart Lung* 2006;**35**:58–65.
24. **Cherniack NS**, Dowling HF, Carton RW, *et al*. The role of acute lower respiratory infection in causing pulmonary insufficiency in bronchiectasis. *Ann Intern Med* 1967;**66**:489–97.
25. **Stockley RA**. Role of bacteria in the pathogenesis and progression of acute and chronic lung infection. *Thorax* 1998;**53**:58–62.
26. **Hill SL**, Morrison HM, Burnett D, *et al*. Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation. *Thorax* 1986;**41**:559–65.
27. **Ho PL**, Chan KN, Ip MS, *et al*. The effect of *Pseudomonas aeruginosa* infection on clinical parameters in steady-state bronchiectasis. *Chest* 1998;**114**:1594–8.
28. **Cabello H**, Torres A, Celis R, *et al*. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. *Eur Respir J* 1997;**10**:1137–44.
29. **Wilson CB**, Jones PW, O'Leary CJ, *et al*. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. *Eur Respir J* 1997;**10**:1754–60.
30. **Evans SA**, Turner SM, Bosch BJ, *et al*. Lung function in bronchiectasis: the influence of *Pseudomonas aeruginosa*. *Eur Respir J* 1996;**9**:1601–4.
31. **Ooi GC**, Khong PL, Chan-Yeung M, *et al*. High-resolution CT quantification of bronchiectasis: clinical and functional correlation. *Radiology* 2002;**225**:663–72.
32. **Failla ML**. Trace elements and host defense: recent advances and continuing challenges. *J Nutr* 2003;**133**:1443–7S.
33. **Fatmi Z**, White F. A comparison of 'cough and cold' and pneumonia: risk factors for pneumonia in children under 5 years revisited. *Int J Infect Dis* 2002;**6**:294–301.
34. **Gracey M**. Nutrition and infections in Australian aboriginal children. *Aust NZ J Med* 1991;**21**:921–7.
35. **Katsura H**, Ogata M, Kida K. Factors determining outcome in elderly patients with severe COPD on long-term domiciliary oxygen therapy. *Monaldi Arch Chest Dis* 2001;**56**:195–201.
36. **Hatt LE**, Waters HR. Determinants of child morbidity in Latin America: a pooled analysis of interactions between parental education and economic status. *Soc Sci Med* 2006;**62**:375–86.
37. **Altin R**, Savranlar A, Kart L, *et al*. Presence and HRCT quantification of bronchiectasis in coal workers. *Eur J Radiol* 2004;**52**:157–63.
38. **Li JS**, Peat JK, Xuan W, *et al*. Meta-analysis on the association between environmental tobacco smoke (ETS) exposure and the prevalence of lower respiratory tract infection in early childhood. *Pediatr Pulmonol* 1999;**27**:5–13.
39. **Ezzati M**, Kammen D. Indoor air pollution from biomass combustion and acute respiratory infections in Kenya: an exposure-response study. *Lancet* 2001;**358**:619–24.
40. **Uttell MJ**, Frampton MW. Acute health effects of ambient air pollution: the ultrafine particle hypothesis. *J Aerosol Med* 2000;**13**:355–9.
41. **Brook I**, Finegold SM. Bacteriology and therapy of lung abscess in children. *J Pediatr* 1979;**94**:10–2.
42. **Scannapieco FA**, Ho AW. Potential associates between chronic respiratory disease and periodontal disease: analysis of National Health and Nutrition Examination Survey III. *J Periodontol* 2001;**72**:50–6.
43. **Tsang KW**, Lam WK, Kwok E, *et al*. *Helicobacter pylori* and upper gastrointestinal symptoms in bronchiectasis. *Eur Respir J* 1999;**14**:1345–50.
44. **Twiss J**, Stewart AW, Byrnes CA. Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis. *Thorax* 2006;**61**:414–8.
45. **Chang AB**, Masel JP, Boyce NC, *et al*. Non-CF bronchiectasis-clinical and HRCT evaluation. *Pediatr Pulmonol* 2003;**35**:477–83.
46. **Field CE**. Bronchiectasis: Third report on a follow-up study of medical and surgical cases from childhood. *Arch Dis Child* 1969;**44**:551–61.
47. **Bahous J**, Cartier A, Pneau L, *et al*. Pulmonary function tests and airway responsiveness to methacholine in chronic bronchiectasis of the adult. *Bull Eur Physiopathol Respir* 1984;**20**:375–80.
48. **Khalid M**, Saleemi S, Zeitouni M, *et al*. Effect of obstructive airway disease in patients with non-cystic fibrosis bronchiectasis. *Ann Saudi Med* 2004;**24**:284–7.
49. **Chang AB**, Lasserson TJ, Kilander TO, *et al*. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. *BMJ* 2006;**332**:11–7.
50. **Gibson PG**, Henry R, Coughlan J. Gastro-oesophageal reflux treatment for asthma in adults and children. *Cochrane Database Syst Rev* 2003;(1).
51. **Cole PJ**. Inflammation: a two edged sword. The model of bronchiectasis. *Eur J Respir Dis Suppl* 1986;**147**:6–15.
52. **Ip M**, Lauder IJ, Wong WY, *et al*. Multivariate analysis of factors affecting pulmonary function in bronchiectasis. *Respiration* 1993;**60**:45–50.
53. **Zheng L**, Lam WK, Tipoe GL, *et al*. Overexpression of matrix metalloproteinase-8 and -9 in bronchiectatic airways in vivo. *Eur Respir J* 2002;**20**:170–6.
54. **Angrill J**, Agusti C, de Celis R, *et al*. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. *Am J Respir Crit Care Med* 2001;**164**:1628–32.
55. **Zheng L**, Tipoe G, Lam WK, *et al*. Up-regulation of circulating adhesion molecules in bronchiectasis. *Eur Respir J* 2000;**16**:691–6.
56. **Angrill J**, Agusti C, de Celis R, *et al*. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. *Thorax* 2002;**57**:15–9.
57. **Ip M**, Shum D, Lauder I, *et al*. Effect of antibiotics on sputum inflammatory contents in acute exacerbations of bronchiectasis. *Respir Med* 1993;**87**:449–54.
58. **Lin HC**, Cheng HF, Wang CH, *et al*. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. *Am J Respir Crit Care Med* 1997;**155**:2024–9.
59. **Watt AP**, Brown V, Courtney J, *et al*. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. *Thorax* 2004;**59**:231–6.
60. **Chan TB**, Arm JP, Anderson J, *et al*. Pulmonary epithelial permeability in bronchiectasis. *Br J Dis Chest* 1988;**82**:56–63.
61. **Klingman KL**, Pye A, Murphy TF, *et al*. Dynamics of respiratory tract colonization by *Branhamella catarrhalis* in bronchiectasis. *Am J Respir Crit Care Med* 1995;**152**:1072–8.
62. **Chan TH**, Ho SS, Lai CK, *et al*. Comparison of oral ciprofloxacin and amoxycillin in treating infective exacerbations of bronchiectasis in Hong Kong. *Chemotherapy* 1996;**42**:150–6.
63. **Chan CH**, Ho AK, Chan RC, *et al*. Mycobacteria as a cause of infective exacerbation in bronchiectasis. *Postgrad Med J* 1992;**68**:896–9.
64. **Wickremasinghe M**, Ozerovitch LJ, Davies G, *et al*. Non-tuberculous mycobacteria in patients with bronchiectasis. *Thorax* 2005;**60**:1045–51.
65. **Judson MA**. Noninvasive Aspergillus pulmonary disease. *Semin Respir Crit Care Med* 2004;**25**:203–19.
66. **Van Devanter DR**, Van Dalfsen JM. How much do *Pseudomonas* biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis? *Pediatr Pulmonol* 2005;**39**:504–6.
67. **Ellerman A**, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. *Eur Respir J* 1997;**10**:2376–9.
68. **Martinez Garcia MA**, de R, Nauffal M, *et al*. Respiratory disorders in common variable immunodeficiency. *Respir Med* 2001;**95**:191–5.
69. **Martinez-Garcia MA**, Perpina-Tordera M, Roman-Sanchez P, *et al*. Quality-of-life determinants in patients with clinically stable bronchiectasis. *Chest* 2005;**128**:739–45.
70. **Munro NC**, Currie DC, Garbett ND, *et al*. Chest pain in chronic sputum production: a neglected symptom. *Respir Med* 1989;**83**:339–41.
71. **Wilson CB**, Jones PW, O'Leary CJ, *et al*. Validation of the St George's Respiratory Questionnaire in bronchiectasis. *Am J Respir Crit Care Med* 1997;**156**:536–41.
72. **FitzGerald JM**, Gibson PG. Asthma exacerbations. 4: Prevention. *Thorax* 2006;**61**:992–9.
73. **Donaldson GC**, Wedzicha JA. COPD exacerbations. 1: Epidemiology. *Thorax* 2006;**61**:164–8.
74. **O'Leary CJ**, Wilson CB, Hansell DM, *et al*. Relationship between psychological well-being and lung health status in patients with bronchiectasis. *Respir Med* 2002;**96**:686–92.
75. **Marchant JM**, Masel JP, Dickinson FL, *et al*. Application of chest high-resolution computer tomography in young children with cystic fibrosis. *Pediatr Pulmonol* 2001;**31**:24–9.
76. **Chan SL**, Chan-Yeung MM, Ooi GC, *et al*. Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis. *Chest* 2002;**122**:2030–7.
77. **Nicotra MB**. Bronchiectasis. *Semin Respir Infect* 1994;**9**:31–40.
78. **Currie DC**, Cooke JC, Morgan AD, *et al*. Interpretation of bronchograms and chest radiographs in patients with chronic sputum production. *Thorax* 1987;**42**:278–84.
79. **Reiff DB**, Wells AU, Carr DH, *et al*. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. *AJR Am J Roentgenol* 1995;**165**:261–7.
80. **Webb WR**, Muller NL, Naidich DP. Airway diseases. In: *High-resolution CT of the lung*. Philadelphia: Lippincott, Williams and Wilkins, 2001;**3**:467–546.
81. **Roberts HR**, Wells AU, Milne DG, *et al*. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. *Thorax* 2000;**55**:198–204.
82. **de Gonzalez AB**, Samet JM. What are the cancer risks from using chest computed tomography to manage cystic fibrosis? *Am J Respir Crit Care Med* 2006;**173**:139–40.
83. **Brenner DJ**. Estimating cancer risks from pediatric CT: going from the qualitative to the quantitative. *Pediatr Radiol* 2002;**32**:228–31.
84. **Loukides S**, Horvath I, Wodehouse T, *et al*. Elevated levels of expired breath hydrogen peroxide in bronchiectasis. *Am J Respir Crit Care Med* 1998;**158**:991–4.
85. **Horvath I**, Loukides S, Wodehouse T, *et al*. Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress. *Thorax* 1998;**53**:867–70.
86. **Kharitonov SA**, Wells AU, O'Connor BJ, *et al*. Elevated levels of exhaled nitric oxide in bronchiectasis. *Am J Respir Crit Care Med* 1995;**151**:1889–93.

87. **Wark PA**, Salto N, Simpson J, *et al*. Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis. *Eur Respir J* 2000;**16**:1095–101.
88. **Anderson SD**, Brannan JD. Methods for “indirect” challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols. *Clin Rev Allergy Immunol* 2003;**24**:27–54.
89. **Akalin F**, Koroglu TF, Bakac S, *et al*. Effects of childhood bronchiectasis on cardiac functions. *Pediatr Int* 2003;**45**:169–74.
90. **Edwards EA**, Narang I, Li A, *et al*. HRCT lung abnormalities are not a surrogate for exercise limitation in bronchiectasis. *Eur Respir J* 2004;**24**:538–44.
91. **Swaminathan S**, Kuppura KV, Somu N, *et al*. Reduced exercise capacity in non-cystic fibrosis bronchiectasis. *Indian J Pediatr* 2003;**70**:553–6.
92. **Sheehan RE**, Wells AU, Copley SJ, *et al*. A comparison of serial computed tomography and functional change in bronchiectasis. *Eur Respir J* 2002;**20**:581–7.
93. **Yang IA**, Kim ST, Bell SC. Antibiotics in COPD, bronchiectasis and cystic fibrosis. In: Gibson PG, ed. *Evidence based respiratory medicine*. Malden, Massachusetts: Blackwells, 2005:389–415.
94. **Drobnic ME**, Sune P, Montoro JB, *et al*. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with *Pseudomonas aeruginosa*. *Ann Pharmacother* 2005;**39**:39–44.
95. **Scheinberg P**, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. *Chest* 2005;**127**:1420–6.
96. **Orriols R**, Roig J, Ferrer J, *et al*. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by *Pseudomonas aeruginosa*. *Respir Med* 1999;**93**:476–80.
97. **Koh YY**, Lee MH, Sun YH, *et al*. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. *Eur Respir J* 1997;**10**:994–9.
98. **Evans DJ**, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis. *Cochrane Database Syst Rev* 2003;(4).
99. **Evans DJ**, Greenstone M. Long-term antibiotics in the management of non-CF bronchiectasis—do they improve outcome? *Respir Med* 2003;**97**:851–8.
100. **Llewellyn-Jones CG**, Johnson MM, Mitchell JL, *et al*. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. *Eur Respir J* 1995;**8**:1479–87.
101. **Crockett AJ**, Cranston JM, Latimer KM, *et al*. Mucolytics for bronchiectasis. *Cochrane Database Syst Rev* 2001;(1).
102. **ten Hacken N**, Kerstjens H, Postma D. Bronchiectasis. *Clinical Evidence* 2005 (accessed 15 Feb 2006).
103. **Jones AP**, Rowe BH. Bronchopulmonary hygiene physical therapy for chronic obstructive pulmonary disease and bronchiectasis. *Cochrane Database Syst Rev* 1998;(4).
104. **Wills P**, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. *Cochrane Database Syst Rev* 2002;(1).
105. **Kellett F**, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. *Respir Med* 2005;**99**:27–31.
106. **Lasserson TJ**, Holt K, Milan SJ, *et al*. Oral steroids for bronchiectasis (stable and acute exacerbations). *Cochrane Database Syst Rev* 2001;(2).
107. **Lasserson T**, Holt K, Evans D, *et al*. Anticholinergic therapy for bronchiectasis. *Cochrane Database Syst Rev* 2001;(2).
108. **Franco F**, Sheikh A, Greenstone M. Short acting beta-2 agonists for bronchiectasis. *Cochrane Database Syst Rev* 2003;(1).
109. **Sheikh A**, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis. *Cochrane Database Syst Rev* 2001;(4).
110. **Corless JA**, Warburton CJ. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis. *Cochrane Database Syst Rev* 2000;(2).
111. **Bradley J**, Moran F, Greenstone M. Physical training for bronchiectasis. In: *Cochrane Library*. *Cochrane Database Syst Rev* 2002;(2).
112. **Newall C**, Stockley RA, Hill SL. Exercise training and inspiratory muscle training in patients with bronchiectasis. *Thorax* 2005;**60**:943–8.
113. **Wedzicha JA**, Muir JF. Noninvasive ventilation in chronic obstructive pulmonary disease, bronchiectasis and cystic fibrosis. *Eur Respir J* 2002;**20**:777–84.
114. **Cranston JM**, Crockett AJ, Moss JR, *et al*. Domiciliary oxygen for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2005;(4).
115. **Corless JA**, Warburton CJ. Surgery versus non-surgical treatment for bronchiectasis. *Cochrane Database Syst Rev* 2000;(4).
116. **McCool FD**. Global physiology and pathophysiology of cough: ACCP evidence-based clinical practice guidelines. *Chest* 2006;**129**:48–53S.
117. **Otgun I**, Karnak I, Tanyel FC, *et al*. Surgical treatment of bronchiectasis in children. *J Pediatr Surg* 2004;**39**:1532–6.
118. **Dupont M**, Gacouin A, Lena H, *et al*. Survival of patients with bronchiectasis after the first ICU stay for respiratory failure. *Chest* 2004;**125**:1815–20.
119. **Conaty S**, Watson L, Dinnes J, *et al*. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. *Vaccine* 2004;**22**:3214–24.
120. **Benhamou D**, Muir JF, Raspaud C, *et al*. Long-term efficiency of home nasal mask ventilation in patients with diffuse bronchiectasis and severe chronic respiratory failure: a case-control study. *Chest* 1997;**112**:1259–66.
121. **Gacouin A**, Desruets B, Lena H, *et al*. Long-term nasal intermittent positive pressure ventilation (NIPPV) in sixteen consecutive patients with bronchiectasis: a retrospective study. *Eur Respir J* 1996;**9**:1246–50.
122. **French J**, Bilton D, Campbell F. Nurse specialist care for bronchiectasis. *Cochrane Database Syst Rev* 2003;(1).
123. **Parameswaran K**, Pizzichini MM, Li D, *et al*. Serial sputum cell counts in the management of chronic airflow limitation. *Eur Respir J* 1998;**11**:1405–8.
124. **Jones AP**, Wallis CE, Kearney CE. Recombinant human deoxyribonuclease for cystic fibrosis. *Cochrane Database Syst Rev* 2003;(3).
125. **O'Donnell AE**, Barker AF, Ilowite JS, *et al*. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. *Chest* 1998;**113**:1329–34.
126. **British Thoracic Society**. Non-invasive ventilation in acute respiratory failure. *Thorax* 2002;**57**:192–211.
127. **Daviskas E**, Anderson SD, Eberl S, *et al*. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. *Am J Respir Crit Care Med* 1999;**159**:1843–8.
128. **Steele K**, Greenstone M, Lasserson JA, *et al*. Oral methylxanthines for bronchiectasis. *Cochrane Database Syst Rev* 2001;(1).
129. **Aaron SD**, Vandemheen KL, Ferris W, *et al*. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. *Lancet* 2005;**366**:463–71.